Comparative Pharmacology
Head-to-head clinical analysis: EMPRACET W CODEINE PHOSPHATE 4 versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPRACET W CODEINE PHOSPHATE 4 versus METHADOSE.
EMPRACET W/ CODEINE PHOSPHATE #4 vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine by CYP2D6, acting as a mu-opioid receptor agonist. Acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways, reducing pain and fever.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
1-2 tablets (acetaminophen 300 mg / codeine phosphate 60 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets per day.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Acetaminophen: 2-3 hours (prolonged in hepatic insufficiency). Codeine: 2.5-3.5 hours; morphine (active metabolite): 1.5-4.5 hours.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal: ~90% as unchanged acetaminophen and metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), 5% unchanged; codeine: ~90% renal as metabolites (codeine-6-glucuronide, norcodeine, morphine, morphine-3-glucuronide, morphine-6-glucuronide), <15% unchanged.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist